Avance Clinical Honored with Frost & Sullivan's 2025 Global Customer Value Leadership Award for Transformative Biotech CRO Services
This award recognizes Avance Clinical's strategic innovation, operational agility, and unwavering commitment to client success in early-phase clinical trials.
SAN ANTONIO, May 14, 2025 /CNW/ -- Frost & Sullivan has named Avance Clinical the recipient of its 2025 Global Customer Value Leadership Award in the biotech contract research organization (CRO) sector, highlighting the company's outstanding performance in delivering exceptional client value through innovation, service excellence, and technology-enabled trial optimization. The accolade reinforces Avance Clinical's position as a trusted CRO partner that is uniquely equipped to support biotech sponsors navigating the complexities of early-phase research.
Each year, Frost & Sullivan undertakes a comprehensive, independent analysis to benchmark companies on two core criteria—strategy alignment and execution effectiveness. Avance Clinical demonstrated clear leadership across both dimensions, offering a compelling combination of agility, scientific rigor, and digital innovation that continues to shape the biotech CRO landscape.
According to Unmesh Lal, Vice President - Healthcare & Life Sciences at Frost & Sullivan, "Avance Clinical is positioning itself as a next-generation CRO with a deeply patient-centric and globally adaptive model. Under Yvonne Lungershausen's leadership, the company is striking a rare balance between innovation and regulatory rigor—leveraging technology to accelerate clinical trials while preserving scientific integrity. Their strategic focus on partnerships to drive global expansion, coupled with strong client retention and a commitment to quality, makes Avance a compelling player in the evolving biotech services landscape.
Avance Clinical's growth strategy is built on its ability to anticipate and respond to market shifts, whether through digital transformation, data-driven decision-making, or strategic geographic expansion. The company's integration of artificial intelligence into core clinical operations—such as protocol development, medical writing, and workforce optimization—enables faster, more reliable outcomes for biotech innovators.
By embedding intelligent automation into traditional manual workflows, Avance Clinical helps clients streamline study timelines while upholding the highest regulatory compliance and scientific integrity standards. These capabilities have positioned the company as a go-to CRO for sponsors seeking speed, quality, and flexibility in their clinical programs.
Avance Clinical Chief Executive Officer, Yvonne Lungershausen said, "We are honored to receive this recognition from Frost & Sullivan, whose deep industry expertise and thoughtful analysis have been invaluable in highlighting what truly matters to our customers. At Avance Clinical, we are driven to be a smarter, faster, and more strategic partner for our clients because every patient deserves a future — that mission is at the heart of everything we do."
Beyond its technical strengths, Avance Clinical distinguishes itself through a deeply customer-focused model. Through real-time milestone reviews, proactive risk mitigation, and transparent communication, the company fosters long-term client relationships built on trust, performance, and shared goals. Its structured project oversight, workforce training, and quality framework consistently drive high satisfaction and retention rates among biotech sponsors worldwide.
Frost & Sullivan recognizes Avance Clinical's ability to translate strategic foresight into measurable impacts, supporting biotech sponsors as they navigate increasing regulatory scrutiny, financial pressures, and extended development timelines. The company's dedication to continuous improvement, global expansion, and collaborative innovation ensures its clients remain competitive in a fast-changing market.
The Global Customer Value Leadership Award is one of Frost & Sullivan's highest honors, presented to organizations that elevate industry standards through breakthrough strategies and customer-centric delivery. Winners are selected based on demonstrated excellence in driving customer success, strengthening market standing, and translating strategic vision into scalable, high-impact outcomes.
Frost & Sullivan's Best Practices Awards are the result of extensive independent research, comparing market participants on performance indicators such as growth strategy, innovation, customer engagement, and operational execution. The awards celebrate companies that have risen above the competition to deliver best-in-class results and set benchmarks for success across global industries.
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Contact:
Tarini Singh
E:
About Avance Clinical
Avance Clinical is a leading Contract Research Organization (CRO) offering biotech companies faster, more flexible, and higher-quality clinical trial services. As the largest premium full-service CRO headquartered in Australia, Avance Clinical delivers globally accepted data across Australia, New Zealand, Asia, North America, and Europe for international biotechs. With 30 years of experience and expertise spanning over more than 250 indications, the company provides comprehensive clinical research services from early to late-phase trials.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
35 minutes ago
- Globe and Mail
Frost & Sullivan: iRegene Therapeutics Honored as "2025 Forbes China Leading Enterprises in Industry Development"
Shanghai, China--(Newsfile Corp. - June 8, 2025) - Recently, The "2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor," jointly organized by Frost & Sullivan and Forbes China, was successfully held at Regent Shanghai on The Bund. Amid the global trend of industrial innovation, the results of the "2025 Pioneer Innovators in Industry Development" selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. iRegene Therapeutics was honored as one of Forbes China's 2025 Leading Enterprises in Industry Development. iRegene is pioneering the future of regenerative medicine with its AI-powered, chemically induced cell therapy platform. By combining cutting-edge technology, a robust R&D ecosystem, and a globally experienced leadership team, iRegene is redefining allogeneic therapies to make them safer, more effective, and broadly accessible. This recognition highlights iRegene's continued leadership in innovation and its commitment to transforming patient care through next-generation regenerative therapies. iRegene Therapeutics Honored as 2025 Forbes China Leading Enterprises in Industry Development Aroop Zutshi, Global Managing Partner and Executive Board Director of Frost & Sullivan, and Junyi Guo, General Manager of Business Operations at Forbes China, jointly presented the 2025 Forbes China Leading Enterprises in Industry Development award. Dr. Jun Wei, Chairman of iRegene Therapeutics, was invited to attend the gala. AI-Driven Chemical-Induced Cell Therapy: Reshaping the Future of Accessible Cell Therapy Since its establishment in 2017, iRegene Therapeutics has remained committed to addressing unmet clinical needs through the development of next-generation cell therapies. With a focus on chemically induced, universal cell therapy products, iRegene aims to deliver transformative treatments for patients with currently incurable diseases. iRegene Therapeutics has a proprietary, AI-based platform for screening chemical compounds to modify specific cellular functions. The platform leverages induced pluripotent stem cells (iPSCs) to enhance treatment potential. By combining compounds to form a chemically induced culture medium, the "AI+Chem" platform can efficiently and precisely reprogram or optimize a cell's fate and function, thereby enhancing the clinical capabilities of cell therapies. With a focus on the chemical induction system, iRegene has developed a comprehensive research and development (R&D) ecosystem and an international patent system that spans the industry. This ecosystem combines the discovery of 'cell fate determinants', the screening of chemical inducers and the validation of cellular function. The system does not use viral vector construction or transgenic methods; the straightforward CMC procedure is cost-efficient. Furthermore, cell transformation and functional optimization are entirely driven by the cells' natural genetic makeup. Transformation is synchronous under chemically enhanced regulation, eliminating the risk of genetic modification. iRegene's pioneering platform has been proven through the positive outcomes of the Phase I clinical trial. In addition, iRegene's executive team has an international perspective, with all members having successful overseas experience in their specialized fields. CEO Dr Wei Jun is a leading expert in regenerative medicine and the induced pluripotent stem cell (iPSC) technology, bringing strategic leadership to the company. Chief Medical Officer Dr Cai Meng has extensive experience taking innovative therapies from discovery through clinical development, while Chief Quality Officer Ren Xiang is a senior regulatory expert who provides solid support from IND approval to NDA clearance in China, the US, and other countries. Executive Vice President Emmanuel Montet, formerly Vice President of the Asia-Pacific region at Ipsen, now leads iRegene's global business development and international strategy. To accelerate global clinical translation and commercialization, iRegene places great emphasis on the philosophy of 'cooperation and mutual benefit'. At the end of 2021, iRegene entered a long-term collaboration with Danaher Corporation to co-develop next-generation platforms for clinical application. Under this partnership, Danaher will play an active role in developing multi-directional platforms for future iRegene Therapeutics projects. This will involve supplying advanced detection instruments and technical resources relating to life sciences research, the development of effective compounds and screening, multi-omics cell mechanism research, and multi-substance screening. Danaher will help iRegene Therapeutics to enhance the efficiency of platform construction and its ability to deliver practical solutions. Danaher will also support iRegene Therapeutics in developing distinctive, innovative drug pipelines and establishing a research and production base. This strategic cooperation has recently been elevated to the iRegene - Danaher Joint Innovation Center, which is the world's first "Joint Innovation Center for Chemically Induced Therapies and Microphysiology Systems". The center will focus on integrating artificial intelligence (AI)-driven chemically induced cell therapy R&D with microphysiology systems technology. It is committed to accelerating the clinical translation and application of innovative therapies, and providing patients globally with more precise and effective treatment solutions for diseases. Danaher will fully support iRegene Therapeutics' future planning and development, aiming to jointly advance innovative development in China's life sciences research. iRegene's breakthrough technology platform, strategic advantages and dedicated team have secured continuous support from several leading venture capital firms, with cumulative financing reaching nearly 400 million RMB (55.5 million USD). The company is advancing multiple programs through clinical development, targeting a win-win situation for its products and the capital markets alike, while providing patients around the world with next-generation chemically induced cell therapies that can genuinely reverse disease progression. About iRegene Therapeutics iRegene Therapeutics is a biotechnology company committed to becoming a global leader in universal chemical-induced cell therapy. As one of the first companies to harness AI and + chemical induction for the specific functional modification of cells, iRegene offers a safer, more scalable, and cost-effective alternative to traditional gene or cell therapies. Its pipeline targets diseases with high unmet need, including neurodegenerative disorders such as Parkinson's disease and blindness. Through pioneering science, strategic global partnerships, and a visionary leadership team, iRegene is reshaping the future of regenerative medicine - making advanced therapies accessible to patients worldwide. In August 2023, the NMPA approved the commencement of Phase I clinical trials for iRegene's first product: 'Human Dopaminergic Precursor Cell, NouvNeu001'. This product was developed using the 'AI+ Chem' platform. This made it the world's first chemically induced pluripotent stem cell (iPSC)-derived therapy to enter clinical trials. In June 2024, it was approved by the U.S. FDA for overseas clinical trials. Even more groundbreakingly, in March 2024, iRegene's 'Chemical Induction Platform' became the first system ever to be granted exemption by the FDA. The company's second product, NouvNeu003, which is intended for the treatment of early-onset Parkinson's disease, received NMPA approval in December 2023 and entered Phase I clinical trials. Both NouvNeu001 and NouvNeu003 have now completed Phase I trials. The Phase I results demonstrate good safety, tolerability, and encouraging efficacy in improving motor and non-motor symptoms. The Phase II trial for NouvNeu001 began in April 2025. In parallel, iRegene's first-in-class ophthalmic therapy, was granted Orphan Drug Designation (ODD) by the U.S. FDA in March 2024.
Cision Canada
38 minutes ago
- Cision Canada
MEXC Unveils New Launchpad Featuring BTC to Kick Off BTC Trading Month
VICTORIA, Seychelles, June 8, 2025 /CNW/ -- In a bold move to restore fairness in early-stage token investing, MEXC, a leading global cryptocurrency exchange, has officially launched its new Launchpad. The platform is designed to offer users fair and transparent access to high-quality tokens. By removing barriers to entry and offering discounted subscriptions to premium assets, it gives equal opportunity to all users, regardless of account status, trading volume, or social influence. The first subscription event under this new model will feature Bitcoin (BTC), marking a high-trust starting point and kicking off its BTC Trading Month. While many launchpads promise community access, most have evolved into tiered, opaque systems where venture capitalists, influencers, and VIPs secure favorable allocations — leaving regular users with scraps. MEXC's new launchpad model challenges this status quo by removing lotteries, VIP tiers, and preferential pools. Instead, it introduces a fully transparent, contribution-based allocation mechanism that puts retail users and large investors on equal footing. "The spirit of launchpads has been lost in recent years," said Tracy Jin, COO of MEXC. "We're bringing it back — by making early-stage investing truly community-first again." Participation in the MEXC Launchpad is open to everyone. Users can directly subscribe to project offerings using USDT or other designated tokens. Allocations are distributed on a purely proportional basis, with simple tasks, point farming, or influencer-driven campaigns involved. There are two primary models available: full subscription, where tokens are allocated directly based on the invested amount, and oversubscription, where allocations are shared proportionally among participants when demand exceeds supply. Building on this structure, participants will also be able to subscribe to tokens at discounted rates below the expected market price, increasing their potential upside. MEXC Launchpad is not limited to early-stage projects; it will also provide access to premium, well-established tokens with strong fundamentals and market appeal. The first subscription event under this new model will feature Bitcoin (BTC), marking a high-trust starting point. The subscription period will run from June 6 to June 20 and includes exclusive offers tailored to different user segments. New users will be able to purchase BTC at a discount of up to 90%, with individual allocations ranging from 5 to 55 USDT, and a total pool capped at 4 BTC. Existing users will receive a 20% discount, with allocation limits set between 25 and 250 USD1, and a total cap of 3 BTC. To further encourage participation, a referral rewards program offers 5 USDT for each new user referred, up to a maximum of 100 USDT per participant. MEXC Launchpad will focus on selecting high-quality projects, particularly in trending and high-growth sectors such as Real World Assets, AI, and the TON ecosystem. Each project is evaluated in collaboration with MEXC Ventures, which provides further support and funding to help innovative ideas scale. Most significantly, no venture capital or KOL pools exist within MEXC Launchpad. All allocations happen on-chain, using a transparent algorithm based solely on each user's actual contribution. This removes the structural favoritism that has plagued traditional launchpads. "We believe innovation should be accessible to everyone," MEXC's Jin said. "You shouldn't have to be a whale, influencer, or VC to get early access to good projects. Our goal is to level the playing field and empower all users to access high-quality projects at favorable terms. With the new Launchpad, we're making it easier for real users to engage with real innovation, without the usual barriers or preferential treatment." As the crypto market continues to heat up, MEXC Launchpad offers something rare: a chance for everyday users to participate in the next wave of innovation, without being pushed aside by insiders. About MEXC Founded in 2018, MEXC is committed to being "Your Easiest Way to Crypto." Serving over 40 million users across 170+ countries, MEXC is known for its broad selection of trending tokens, everyday airdrop opportunities, and low trading fees. Our user-friendly platform is designed to support both new traders and experienced investors, offering secure and efficient access to digital assets. MEXC prioritizes simplicity and innovation, making crypto trading more accessible and rewarding.
Cision Canada
5 hours ago
- Cision Canada
THE BANFF WORLD MEDIA FESTIVAL AND PARAMOUNT+ IN CANADA ANNOUNCE 'SEASON TWO' RENEWAL OF BANFF SPARK: PRODUCERS EDITION
The Call for Applications will be announced in August, 2025 BANFF, AB and TORONTO, June 8, 2025 /CNW/ -- The Banff World Media Festival (BANFF) is pleased to announce that Paramount+ in Canada has renewed the BANFF SPARK Accelerator for Women in the Business of Media: Producers Edition for a second year. The program renewal was announced today during the opening ceremonies of the 46th edition of the Banff World Media Festival, taking place at the Fairmont Banff Springs Hotel from June 8-11, 2025. This national program is open to Canadian women, (including non-binary individuals), from across the country and is aimed at working toward gender parity in the media industry by supporting growth, investment, scaling, and sustainability of women-owned media companies. Twenty-five (25) women who own their own production outfits will participate in: a series of customized, virtual sessions covering high-level aspects of business strategy and planning, finance, and marketing best practices; one-on-one 'concierged' meetings with individuals, and curated sessions during the Banff World Media Festival. They will also benefit from a significant marketing and promotional campaign to help build their business profile in the industry. Participants receive a Banff World Media Festival pass, and a travel stipend to offset costs of attending the Festival. "Paramount+ in Canada has been an incredible and committed partner to advancing gender parity in our industry. This first-of-its-kind program has already generated positive career growth for more than 225 women participants by helping them form strategic partnerships, and hone their business skills. Despite the achievements and progress made, our industry still has work to do in breaking down barriers for women, and especially racialized women, to help them gain a foothold in the global marketplace," says Jenn Kuzmyk, Executive Director, Banff World Media Festival. "We are honoured to partner with Banff World Media Festival for a second consecutive year to continue the BANFF Spark Program: Producers Edition," said Vanessa Case, Vice President Content, Paramount+, Canada. "Investing in Canada's up and coming producers isn't just the right thing to do—it's a strategic imperative. Inclusive leadership drives innovation, improves decision-making, and ultimately reflects the audiences we serve." BANFF Spark provides business guidance, and a gateway to the Canadian and global film and television industry through the renowned Banff World Media Festival's (BANFF) conference and marketplace. Programmed through an intersectional lens, the initiative has a core mission to empower women of color, Indigenous women, women with disabilities, 2SLGBTQI+ women, and non-binary individuals to advance both domestically, and across the global media industry. This initiative is the eighth partnership Paramount+ in Canada has announced that reinforces its commitment to inclusivity. In addition to supporting the 2025 and now 2026, the streamer has announced partnerships with the 2024 Reelworld Summit, the, inkcanada to Connect Emerging Writers with Industry Allies; a collaboration with the; a collaboration with the Black Screen Office for the Black Creators Festival Initiative; a joint venture with BIPOC TV & Film and the National Screen Institute Partner for the new ELEVATE program; and partnerships with both The Shine Network Institute (TSNI) for the Indigenous Producers Budgeting Intensive and with the Pacific Screenwriting Program and the Indigenous Screen Office to Create the Indigenous Screenwriters Lab in 2024. About the Banff World Media Festival Now in its 46th year, the Banff World Media Festival (BANFF) and the Rockie Awards host one of the most important global conferences and content development marketplaces - gathering top creators, producers, showrunners, talent, networks, studios, streamers, press and media companies. BANFF's intimate, retreat-style event serves as a leading destination for development, co-production and co-venture partners and offers an unparalleled opportunity for international decision-makers to connect, map the future of the industry, and execute new business deals. Summit Series keynotes, Master Classes and renowned Showrunner Superpanels feature the industry's most inspiring creative and business leaders and give global profile to the most talked-about shows. The Rockie Awards recognize the best content and most influential entertainment industry executives, talent and creators in the world. BANFF continues to deliver important fellowships and initiatives including: the BANFF Spark Accelerator for Women in the Business of Media: Producers Edition, the Netflix-BANFF Diversity of Voices Initiative, and the Indigenous Screen Summit and Pitch Forum. Together these programs have provided more than 1000 opportunities for under-represented professionals in the Canadian media industry. For more information on the Banff World Media Festival, click here. @banffmedia #BANFFMediaFestival #ROCKIEAWARDS About Paramount+ Paramount+ is a global digital subscription video streaming service from Paramount that features a mountain of premium entertainment for audiences of all ages. Internationally, the streaming service features an expansive library of original series, hit shows, and popular movies across every genre from world-renowned brands and production studios, including SHOWTIME®, CBS, Comedy Central, MTV, Nickelodeon, Paramount Pictures, and the Smithsonian Channel™, in addition to a robust offering of premier local content. The service currently lives in the U.S., Canada, the U.K., Australia, Latin America, the Caribbean, Austria, France, Germany, Ireland, Italy, Switzerland and Japan.
